New scientific trials are advancing remedies for cutaneous T-cell lymphoma, superior stable tumors, pediatric sarcomas and ALK-positive lung most cancers.
Current progress in most cancers analysis is driving new remedy choices for folks with cutaneous T-cell lymphoma, superior stable tumors, pediatric sarcomas and ALK-positive lung most cancers. A number of scientific trials have reached necessary milestones, together with new website activations, first affected person dosing and completion of early-phase research.
VCU Massey First U.S. Website in World Part 2a Trial of PTX-100 for Cutaneous T-Cell Lymphoma
VCU Massey Complete Most cancers Middle is the primary website in america to be activated in a world section 2a trial evaluating PTX-100 (also referred to as GGTI-2418) for the remedy of cutaneous T-cell lymphoma, a uncommon and infrequently treatment-resistant type of T-cell lymphoma, in response to a information launch from the most cancers middle.
PTX-100 is a first-in-class small molecule that blocks geranylgeranyl transferase-1, an enzyme concerned in most cancers cell survival.
The worldwide section 2a trial is enrolling folks with relapsed or treatment-resistant cutaneous T-cell lymphoma to additional assess the security and effectiveness of PTX-100. It’s happening at main tutorial most cancers facilities in america, Australia and Europe.
For extra details about the examine or to inquire about eligibility, sufferers and referring physicians can contact Massey’s Scientific Trials Workplace or submit a scientific trial request kind.
First Affected person Dosed in Part 2 of BIPAVE-001 Trial for Superior Stable Tumors
The primary affected person has been dosed within the section 2 portion of the section 1/2 BIPAVE-001 trial evaluating AI-081, a possible best-in-class PD-1 and VEGF bispecific antibody.
The BIPAVE-001 section 1/2 trial is evaluating the security and effectiveness of AI-081, together with how the physique processes the drug, in two elements. Half A is an ongoing first-in-human section 1 examine testing totally different doses in sufferers with superior stable tumors. Half B is the section 2 portion, specializing in discovering the perfect dose by evaluating AI-081 both alone or mixed with customary remedies, relying on most cancers sort. The examine is underway at 11 websites throughout america and has additionally been accepted by China’s regulatory company.
AI-081 is a bispecific antibody that targets PD-1 and VEGF for superior stable tumors. It combines two high-affinity antibodies in a confirmed design to spice up immune response. Preclinical research confirmed AI-081 binds each targets strongly and works higher than related medication by enhancing PD-1 blockade whereas blocking VEGF. This twin motion might enhance remedy effectiveness.
To study extra in regards to the trial, use the scientific trial ID NCT06635785 at clinicaltrials.gov, or go to www.oncoc4.com.
Actuate Completes Part 1 Trial of Elraglusib Combos for Pediatric Most cancers
Actuate Therapeutics introduced the completion of the section 1 portion of its scientific examine evaluating elraglusib monotherapy or together with irinotecan, irinotecan plus temozolomide, or cyclophosphamide plus topotecan in pediatric sufferers with refractory malignancies.
Elraglusib inhibits glycogen synthase kinase-3 beta, a goal concerned in most cancers development. Early indicators of exercise, particularly in treatment-resistant Ewing sarcoma, assist advancing this system to a section 2 examine in kids, adolescents and adults with relapsed or refractory illness.
The open-label Part 1/2 trial enrolled 10 sufferers with relapsed or refractory Ewing sarcoma handled with elraglusib plus topotecan and cyclophosphamide. The examine is ongoing at a number of facilities.
For extra details about the trial or to inquire about eligibility, use the scientific trial ID NCT04239092 at clinicaltrials.gov or contact Actuate Therapeutics.
ALKAZAR Part 3 Trial Evaluating Neladalkib for Lung Most cancers Subset
The primary affected person has been dosed within the section 3 trial ALKAZAR, evaluating neladalkib for tyrosine kinase inhibitor (TKI)-naive sufferers with superior anaplastic lymphoma kinase (ALK)-positive non-small cell lung most cancers, versus Alecensa (alectinib), a front-line customary of care, in response to a information launch from Nuvalent.
Neladalkib is a brain-penetrant ALK inhibitor designed to work in sufferers whose lung most cancers has stopped responding to earlier ALK-targeted remedies, as per the discharge. It might assist management tumors with tough-to-treat mutations and mind metastases whereas avoiding sure unwanted effects linked to different medication.
The ALKAZAR trial is a world section 3 randomized, managed examine. Round 450 sufferers who haven’t beforehand obtained a TKI will likely be enrolled and randomly assigned to obtain both neladalkib or Alecensa. The first endpoint is progression-free survival. Secondary endpoints embrace total survival, progression-free survival by investigator evaluation, time to intracranial response and intracranial goal response charge (assessed by blinded unbiased central overview), intracranial period of response, goal response charge, period of response, time to intracranial development and security.
The trial is recruiting in St. Louis, Missouri and New Hyde Park, New York.
For extra details about the trial or to inquire about eligibility, use the scientific trial ID NCT06765109 at clinicaltrials.gov.
References
- “Massey turns into first U.S. website to enroll sufferers in international section 2a trial of first-in-class remedy for T-cell lymphoma.” VCU Massey Complete Most cancers Middle, July 18, 2025.
- “OncoC4 doses first affected person with potential best-in-class PD-1 VEGF bispecific antibody AI-081 in section 2 portion of BIPAVE-001 trial for superior stable tumors in US.” OncoC4, July 22, 2025.
- “Actuate Therapeutics advances scientific program in Ewing sarcoma after optimistic section 1 trial demonstrates full and partial responses in difficult-to-treat pediatric sarcomas.” Actuate Therapeutics, July 17, 2025.
- “Nuvalent publicizes initiation of ALKAZAR section 3 randomized managed trial evaluating neladalkib for sufferers with TKI-naive ALK-positive NSCLC.” Nuvalent, July 21, 2025.
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
